首页 | 本学科首页   官方微博 | 高级检索  
     


Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis
Authors:Md. Asiful Islam  Fahmida Alam  Cinzia Cavestro  Cornelia Calcii  Teguh Haryo Sasongko  Roger A. Levy  Siew Hua Gan
Affiliation:1. Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia;2. Headache Center, San Lazzaro Hospital, Alba, CN, Italy;3. State University of Medicine and Pharmacy “Nicolae Testemitanu” Chi?in?u, Republic of Moldova;4. Hospital of Mother and Child Health Care, Chi?in?u, Republic of Moldova;5. Division of Human Biology, School of Medicine, International Medical University, 57000 Bukit Jalil, Kuala Lumpur, Malaysia;6. Department of Rheumatology, Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil;7. Global Medical Expert Immuno-inflammation, GlaxoSmithKline (GSK), Upper Providence, PA, USA;8. School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500 Bandar Sunway, Selangor, Malaysia
Abstract:

Background

Autoimmunity is believed to play an important causative role in the pathogenesis of epilepsy. There are evidences for the presence of autoantibodies in patients with epilepsy. To date, many studies have assessed the presence of antiphospholipid antibodies (aPLs) in epilepsy patients, though the relationship has been inconclusive.

Aims

The aim of this systematic review and meta-analysis was to evaluate the presence of aPLs in epileptic patients as compared to healthy controls.

Methods

Five electronic databases (PubMed, Web of Science, Embase, Scopus and Google Scholar) were searched systematically. Study-specific odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using random-effects model. Quality assessment was carried out by using the modified 9-star Newcastle-Ottawa Scale (NOS). L'Abbé plots were generated to visually inspect heterogeneity while publication bias was evaluated via visualization of contour- enhanced funnel plots, and Begg's and Egger's tests.

Results

Based on the inclusion criteria, 14 studies were selected involving 1248 epilepsy patients and 800 healthy controls. The majority of epilepsy was categorised as generalised or partial and none had comorbidity with autoimmune diseases. Significant presence of both anticardiolipin (aCL) antibodies (OR: 5.16, 95% CI: 3.21–8.28, p?p?=?0.04) exhibited comorbid association with epilepsy patients as compared to healthy controls. Subgroup analyses revealed that presence of aCL antibodies was more specifically observed in paediatrics (OR: 4.57, 95% CI: 2.57–8.15, p?p?=?0.001). The odds of aCL antibody presence was higher in partial epilepsy patients (OR: 7.88, 95% CI: 3.23–19.24, p?p?p?=?0.0005) than Europeans (OR: 4.35, 95% CI: 2.74–6.92, p?p?=?0.02) and African population with epilepsies (OR: 10.59, 95% CI: 1.22–92.25, p?=?0.03). NOS of the majority of the studies (11/14) indicated a high methodological quality. No substantial heterogeneity was observed either from the quantitative analysis or from the L'Abbé plots while no significant publication bias was detected from funnel plots; Begg's and Egger's tests.

Conclusion

Since none of the epilepsy subjects exhibited any comorbid autoimmune disorders, significant presence of aCL and anti-β2-GPI antibodies indicate towards their contribution in immune-mediated general pathogenesis of epilepsy.
Keywords:Antiphospholipid antibody  Anticardiolipin antibody  Anti-β2-glycoprotein I antibody  Autoimmune  Epilepsy  Systematic review  Meta-analysis
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号